R-Biopharm announces test to detect monkeypox virus
more
Stories from Darmstadt, Germany
- Language:
- Media:
- Period:
- Period:Total
Merck and BioMed X Institute Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity
Darmstadt, Germany (ots/PRNewswire) - - Merck to support up to six additional research projects at the BioMed X Institute in Heidelberg within the next six years - Call for application for a global crowdsourcing project, 'Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging' Merck, a leading science and ...
moreMerck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
Darmstadt, Germany (ots/PRNewswire) - Not intended for US-, Canada- or UK-based media Merck, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or ...
moreNew Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines
Darmstadt, Germany (ots/PRNewswire) - MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing Initial findings from the CLOCK-MS vaccine ...
moreEuropean Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations
Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial ...
moreMerck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Merck out-licenses Phase IIb-ready atacicept to Vera Therapeutics - Phase IIa trial conducted by Merck shows promising results in IgA nephropathy (IgAN), also known as "Berger's disease" - Out-licencing deal includes 10% equity in Vera Therapeutics and up to EUR 605 million in development ...
moreMerck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis
Darmstadt, Germany (ots/PRNewswire) - - Merck out-licenses promising clinical-stage program to Novartis - Anti-ADAMTS5 Nanobody® programis Phase II-ready with novel MoA which could protect against cartilage damage and reduce joint pain - Merck receives upfront payment of EUR 50 million with the potential of ...
moreMerck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020
Darmstadt, Germany (ots/PRNewswire) - · New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer · Overall efficacy data, and analyses of brain metastases and HRQoL for tepotinib? from ...
moreNew MAVENCLAD® Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting Highlight Rapid Onset of Action and Compelling Post-Approval Safety
Darmstadt, Germany (ots/PRNewswire) - In MAGNIFY-MS, patients experienced a rapid onset of action from end of Month 1 that was significant in all study periods versus baseline Post-approval safety analysis showed no increased risk of viral respiratory infections and lower rates of malignancy than in the clinical ...
moreMerck Announces Positive Phase II Results for Investigational Sonelokinab (M1095) in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Sonelokinab is an investigational IL-17 A/F Nanobody®, which neutralizes both IL-17A and IL-17F - Phase II study was facilitated by Avillion as part of an innovative co-development model Merck, a leading science and technology company, ...
moreMerck to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Company to present 54 abstracts across its MS portfolio - MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib - New long-term data and real-world evidence further characterise efficacy and safety ...
moreStephan Sieber Awarded EUR 1 Million Future Insight Prize 2020 by Merck
Darmstadt, Germany (ots/PRNewswire) - - Prof. Sieber is developing approaches against multi-resistant pathogens at the Technical University of Munich - Inaugural Johann Anton Merck Award presented to Prof. Caroline Dive, Cancer Research UK, for her liquid biopsy research - Sibel Health awarded the Nature Spinoff Prize Merck, a leading science and technology company, ...
moreMerck and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living With MS
Darmstadt, Germany (ots/PRNewswire) - - Merck and Twitch collaborate on World MS Day to increase understanding of the impact of multiple sclerosis (MS) - Livestream event with Twitch influencers on May 30 will raise awareness and money for the MS International Federation and help connect people affected by the disease, in line with official World MS Day theme MS ...
moreBreakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020
Darmstadt, Germany (ots/PRNewswire) - - Results from two studies of BAVENCIO® to be featured in ASCO press briefing - Primary efficacy, biomarker and HRQoL analyses for tepotinib?, the first MET inhibitor to have received a regulatory approval for NSCLC with MET gene alterations - Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa? ...
moreData From Merck at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care
Darmstadt, Germany and New York (ots/PRNewswire) - - Not intended for US-, Canada- or UK-based media - ASCO Abstract # BAVENCIO® (avelumab): LBA1, 5061; Bintrafusp alfa (bifunctional fusion protein): 9558; Tepotinib (MET kinase inhibitor): 9556, 9575. - Late-breaking presentation of Phase III JAVELIN Bladder 100 data for BAVENCIO® showing overall survival benefit in ...
moreERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Darmstadt, Germany (ots/PRNewswire) - Approval is for ERBITUX® in combination with platinum-based therapy with fluorouracil for the first-line treatment of R/M SCCHN Pivotal Phase III study shows significant improvements with ERBITUX® in combination with platinum-based therapy with fluorouracil in response rate, ...
moreMerck Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations
Darmstadt, Germany (ots/PRNewswire) - - Japanese Ministry of Health, Labour and Welfare grants orphan drug designation for diseases that affect fewer than 50,000 patients in Japan, and for which significant unmet medical need exists - MET exon 14 (METex14) skipping alterations and MET amplifications are present in ...
moreEuropean Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Darmstadt, Germany, and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen ...
moreAbstracts highlight data on BAVENCIO as a monotherapy and in combination in multiple advanced cancers
Darmstadt, Germany, and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® (avelumab) alone or as part of combination regimens for the ...
moreNew Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care
Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or the UK Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: ...
moreCHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Darmstadt, Germany and New York, Us (ots/PRNewswire) - Not intended for US, Canada and UK-based media - Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission ...
moreMerck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
Darmstadt, Germany (ots/PRNewswire) - - Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis - The ...
moreUpdated Results for Investigational Therapy Tepotinib Presented at WCLC 2019
Darmstadt, Germany (ots/PRNewswire) - - Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation and select MET dysregulations The ...
moreMerck to Showcase New Data Across MS Portfolio at EAN 2019
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK or U.S. based media - Company to present 16 abstracts on MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib at the 5th Congress of the European Academy of Neurology - Presentations include new data on the long-term efficacy and safety of MAVENCLAD®, new safety data for Rebif® and the 48-week analysis from the Phase 2 ...
moreMerck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations
Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract # Tepotinib (MET kinase inhibitor): 9005 Not intended for UK- , Canada- or US-based media - Alterations of the MET signaling pathway are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis - New interim data from Phase II VISION ...
moreMerck Pioneers New Efforts to See MS From the Inside Out
Darmstadt, Germany (ots/PRNewswire) - Not intended for media in the UK and the U.S. - Company launches global art campaign for people with MS to express their invisible symptoms and the unseen impact of the disease - Thought-provoking campaign coincides with the launch of MSonyourterms.com (http://www.msonmyterms.com/), a resource for patients, carers, and the public to understand MS from the Inside Out - Merck to donate ...
moreMerck Data at ASCO 2019 Showcase Multiple Innovative Molecules with Potential to Impact Unmet Needs in Cancer Care
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- , Canada- or US-based media ASCO Abstract # Bintrafusp alfa (bifunctional fusion protein): TPS9114; Tepotinib (MET kinase inhibitor): 9005; Discovery: 2567; ERBITUX® (cetuximab): 3580; BAVENCIO® (avelumab): 9569; 101; 4552; 4072 - New biomarker analyses ...
morePositive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton´s Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. media - 48-week results provide additional evidence of relapse reduction for investigational evobrutinib - Evobrutinib demonstrated rapid lesion reductions on MRI at week 12 that were maintained through week 48, with no new safety signals identified over 52 ...
moreMerck to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. or U.K. based media - 20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate Merck's commitment and clinical development program in multiple sclerosis Merck, a leading science and technology company, today announced that data from ...
moreFDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's unique mechanism may provide an important new option for patients with ongoing active disease - MAVENCLAD demonstrated significant efficacy ...
more
12345Next